Lecanemab vs donanemab vs aducanumab compared

Mechanism of action: where each antibody intervenes in the Aβ cascade

The three anti-amyloid monoclonal antibodies differ most fundamentally in the stage of amyloid-beta pathology they target — a distinction that shapes everything downstream, from efficacy magnitude to safety profile. Lecanemab acts earliest in the cascade, while donanemab and aducanumab act later against established plaques.

Lecanemab is a humanized IgG1 monoclonal antibody that specifically binds to soluble Aβ oligomers and protofibrils — the early-stage, soluble aggregates that precede plaque formation. Animal studies have demonstrated that lecanemab significantly reduces pathogenic Aβ plaques, inhibits Aβ aggregation, and selectively clears Aβ protofibrils from both brain tissue and cerebrospinal fluid. By intervening at this upstream point, lecanemab aims to prevent the formation and accumulation of larger, more toxic mature plaques.

Donanemab, developed by Eli Lilly, is a recombinant humanized IgG1 monoclonal antibody that works by specifically recognising and clearing deposited Aβ plaques — existing, mature amyloid already laid down in the brain. Its mechanism is characterised by high-affinity clearance of these mature plaques, making it a downstream intervention relative to lecanemab.

Aducanumab also primarily removes deposited plaques, operating at a similar stage in the cascade to donanemab. The key mechanistic distinction therefore separates lecanemab — targeting soluble precursors — from both donanemab and aducanumab, which target insoluble, deposited aggregates. As research tracked by WIPO patent filings has shown, this upstream vs. downstream targeting difference has driven divergent patent landscapes for each asset.

Phase III efficacy outcomes: CDR-SB, iADRS, and amyloid clearance

Lecanemab and donanemab both demonstrated statistically significant cognitive benefits in their respective Phase III programmes, while aducanumab's efficacy remains characterised as controversial — a label that reflects its contested regulatory history rather than a minor empirical uncertainty.

Lecanemab: Clarity AD results

In the Clarity AD Phase III study, lecanemab reduced CDR-SB (Clinical Dementia Rating Scale—Sum of Boxes) scores by 27%. A pooled meta-analysis combining lecanemab and donanemab data showed a CDR-SB score decrease of 0.49 units (95% CI −0.67 to −0.30, P<0.00001) and an ADAS-Cog 14 standardised mean difference of −1.06 (95% CI −1.54 to −0.57, P<0.0001). Notably, this cognitive improvement amplitude is significantly higher than that typically seen with traditional cholinesterase inhibitors, which usually achieve 0.3–0.5 units. Population pharmacokinetic studies for lecanemab indicate that biweekly dosing more rapidly reduces amyloid PET standardised uptake value ratios (SUVr) and plasma p-tau181 levels compared to a 10 mg/kg monthly regimen.

Donanemab: iADRS outcomes

Donanemab delayed iADRS (Integrated Alzheimer's Disease Rating Scale) cognitive decline by 35% in its Phase III trial, with better outcomes specifically in the low/medium tau subgroup. This subgroup finding is clinically significant: it suggests that earlier intervention — before substantial tau pathology accumulates — may be necessary to capture the full benefit of amyloid clearance.

Amyloid clearance magnitude and the efficacy dissociation

The pooled meta-analysis for lecanemab and donanemab showed a combined amyloid load reduction of 72.99 SUVr units (95% CI −88.58 to −57.41, P<0.00001) on PET imaging. This is a substantial radiological signal — yet the same analysis highlights a meaningful dissociation between this amyloid clearance magnitude and the relatively modest cognitive improvement (ADAS-Cog 14 SMD of −1.06). Three explanations are proposed: amyloid clearance requires multiple downstream steps to translate into clinical benefit; continuous tau pathology may offset benefits; and existing cognitive scales may not be sensitive enough to capture the full treatment effect.

"The amplitude of cognitive improvement seen with lecanemab and donanemab — an ADAS-Cog 14 SMD of −1.06 — is significantly higher than that of traditional cholinesterase inhibitors, which typically achieve only 0.3–0.5 units."

ARIA safety profiles: incidence rates, patterns, and genotype risk

Amyloid-related imaging abnormalities (ARIA) represent the most clinically significant safety concern across all three anti-amyloid antibodies. The key distinction is magnitude: aducanumab's ARIA-E incidence of 35% is roughly two to three times higher than lecanemab's Phase III rate of 12.6%–17.3%, and the donanemab group showed a higher ARIA-E risk than lecanemab within the comparative analysis.

Pooled ARIA risk: lecanemab and donanemab

The meta-analysis of lecanemab and donanemab trials found that the relative risk of overall ARIA was 4.35 times higher than in the control group (95% CI 2.41–7.88, P<0.00001). ARIA-E (edema or effusions) risk was increased 8.78-fold (RR=8.78, 95% CI 6.15–12.53, P<0.00001), ARIA-H (hemosiderin deposits) risk was increased 1.94-fold (RR=1.94, 95% CI 1.64–2.29, P<0.00001), and the risk of superficial siderosis of the central nervous system was 2.63 times higher (RR=2.63, 95% CI 1.69–4.10, P<0.0001).

The mechanistic basis of ARIA

ARIA-E and ARIA-H occur because the drugs' mechanism of clearing intracerebral Aβ can accelerate the stripping of Aβ around blood vessels, damaging the vascular basement membrane structure and leading to leakage or haemorrhage. This vascular mechanism is shared across all three antibodies, which is why ARIA risk — while differing in magnitude — is a class-wide concern monitored by regulatory bodies including the FDA and EMA.

APOE ε4 genotype and ARIA risk stratification

The APOE ε4 genotype plays a critical role in modulating ARIA-E risk. Non-carriers have a 10.97-fold increased risk of ARIA-E; heterozygotes a 6.37-fold increased risk; and homozygotes a 10.84-fold increased risk. This is attributed to a dual mechanism: APOE ε4 exacerbates cerebral amyloid angiopathy (CAA) severity and amplifies blood-brain barrier disruption. The counterintuitive finding that non-carriers and homozygotes show similarly elevated risk — both above heterozygotes — underscores the complexity of this genotype-ARIA relationship.

Treatment regimen differences: dosing, duration, and discontinuation

The three antibodies differ substantially in their intended treatment duration — a distinction that has direct implications for patient burden, healthcare resource utilisation, and cost modelling. Donanemab's finite-treatment strategy represents the most clinically novel approach among the three.

Lecanemab: biweekly dosing

Lecanemab is administered on a biweekly basis. Population pharmacokinetic studies demonstrate that this biweekly dosing regimen more rapidly reduces amyloid PET SUVr and plasma p-tau181 levels compared to a 10 mg/kg monthly regimen. For patients with heightened sensitivity to tolerability, gradual dose-escalation regimens have been considered as a risk-mitigation strategy.

Donanemab: the discontinuation strategy

Donanemab's most clinically distinctive feature is that it does not require lifelong administration. Its innovative treatment strategy involves periodic dosing to achieve Aβ plaque clearance, with the potential for treatment discontinuation once clearance is confirmed. This makes donanemab the first Aβ-targeted therapy designed with a finite treatment duration in mind — a significant practical advantage for patients and healthcare systems, and a key differentiator in cost-effectiveness modelling.

Aducanumab: limited regimen detail

The available comparative framework does not provide specific details on aducanumab's dosing frequency or intended treatment duration beyond its general classification as a plaque-clearing antibody. Given its higher ARIA-E incidence and the controversial nature of its efficacy data, its real-world treatment uptake has been limited since its accelerated FDA approval.

Clinical applicability: patient selection, monitoring, and cost

The clinical applicability of all three anti-amyloid antibodies is constrained by strict eligibility requirements, intensive biomarker monitoring demands, and high treatment costs — factors that collectively limit access and necessitate a stratified management approach rather than broad prescribing.

Patient selection criteria

Both lecanemab and donanemab require strict screening of early Alzheimer's disease patients who are Aβ-positive and have tau levels below medium. This dual biomarker requirement — amyloid confirmation plus tau stratification — reflects the Phase III subgroup data showing that patients with higher tau burden derive less benefit. The donanemab Phase III finding of better outcomes in the low/medium tau subgroup directly informs this selection logic. Aducanumab does not have explicitly detailed patient selection criteria in the comparative framework beyond its general early AD indication.

Biomarker monitoring requirements

Treatment with lecanemab and donanemab relies heavily on biomarker monitoring throughout the treatment course. This includes baseline imaging assessments and ongoing MRI monitoring to detect ARIA events. For APOE ε4 homozygous patients, intensified MRI monitoring is recommended: baseline scans followed by monthly evaluations during the first three months of treatment for early ARIA detection. Aducanumab, given its higher ARIA-E incidence of 35%, would similarly require rigorous monitoring protocols, though specific schedules are not detailed in the comparative framework.

Cost-effectiveness implications

Lecanemab's annual treatment cost exceeds USD 26,000. This figure, combined with the costs of biomarker screening, patient selection workup, and ongoing MRI monitoring, represents a substantial economic burden for healthcare systems. Symptomatic therapies — traditional cholinesterase inhibitors and memantine — are noted as being more suitable for a wider patient population, but they cannot delay disease progression, which is the core value proposition of the disease-modifying antibodies. As documented in health economics research published through OECD health policy frameworks, the cost-effectiveness of high-cost disease-modifying therapies for neurodegenerative conditions is acutely sensitive to patient selection precision.

Stratified management framework

The evidence base supports a stratified management strategy that integrates multiple factors. Pretreatment genetic screening — especially for APOE ε4 — serves as a risk stratification tool. Individualised dosing and monitoring plans should be based on APOE ε4 genotype and baseline imaging. Drug selection should integrate patient preferences, anticipated treatment duration (particularly relevant for donanemab's finite-treatment advantage), and healthcare resource accessibility. For patients with heightened tolerability sensitivity, gradual dose-escalation regimens for lecanemab may be appropriate. Increased MRI monitoring frequency is warranted for APOE ε4 carriers or those requiring rapid amyloid plaque clearance.

Five-dimension comparison at a glance

"Donanemab is the first Aβ-targeted therapy that does not require lifelong administration — a finite-treatment strategy that sets it apart from both lecanemab and aducanumab in terms of patient burden and cost modelling."

For R&D teams and IP professionals tracking this therapeutic class, the patent landscape reflects these clinical distinctions: lecanemab's protofibril-targeting mechanism, donanemab's plaque-clearing and discontinuation strategy, and the ARIA risk-mitigation approaches each generate distinct patent clusters. Organisations tracking competitive intelligence in this space should monitor both mechanism-of-action patents and biomarker monitoring method filings, as catalogued in databases maintained by the EPO and reviewed in PatSnap's innovation intelligence resources.